Lv1
50 积分 2021-12-03 加入
ToxicitiesofPARPinhibitorsingenitourinarycancers
1个月前
已关闭
Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis
1个月前
已完结
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
2个月前
已完结
MRG007, a cadherin 17-targeted, glycan-linked, exatecan-based antibody-drug conjugate, demonstrated potent anti-tumor activity and a good safety profile in preclinical studies
3个月前
已关闭
Abstract 1544: MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients
3个月前
已关闭
Fundamental aspects of DMPK optimization of targeted protein degraders
6个月前
已完结
Opinion on Qualitative Severity Descriptors to Express Magnitude of Changes in Clinical Pathology Endpoints in Nonclinical Toxicity Studies
6个月前
已完结
Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
6个月前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
6个月前
已完结
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
7个月前
已完结
皖公网安备34019202002308
